Development of Adoptive Immunotherapy with KK-LC-1-specific TCR-transduced γδT Cells Against Lung Cancer Cells

Overview

Journal Cancer Sci

Specialty Oncology

Date 2020 Aug 12

PMID 32780528

Citations 10

Authors

Yoshinobu Ichiki

Yoshiki Shigematsu

Tetsuro Baba

Hironobu Shiota

Takashi Fukuyama

Yoshika Nagata

Tetsuya So

Manabu Yasuda

Mitsuhiro Takenoyama

Kosei Yasumoto

Affiliations

Soon will be listed here.

Abstract

The present study analyzed the antitumor effect of γδT cells transduced with the TCR of cancer-specific CTLs to establish forceful cancer-specific adoptive immunotherapy. We cloned the TCRαβ genes from CTLs showing HLA-B15 restricted recognition of Kita-Kyushu lung cancer antigen-1 (KK-LC-1), a cancer/germline gene antigen, identified in a lung adenocarcinoma case (F1121). The TCRαβ and CD8 genes were transduced into γδT cells induced from PBLs of healthy volunteers stimulated with zoledronate and IL-2. The KK-LC-1-specific TCRαβ-CD8 γδT cells showed cytotoxic activity against the KK-LC-1 positive lung cancer cell line F1121L and produced IFN-γ against F1121L and KK-LC-1 peptide-pulsed F1121 EBV-B cells. These responses were blocked by HLA class I and HLA-B/C antibodies. An in vivo assay using NOD/SCID mice with xenotransplantation of human lung cancer cells was performed, and the TCRαβ-CD8 transduced γδT cells (TCRαβ-CD8 γδT cells) were intravenously injected. Growth inhibition of KK-LC-1 , HLA-B15 lung cancer cells was confirmed in mice with injection of the TCRαβ-CD8 γδT cells from 1 wk after xenotransplantation of cancer cells but not in those treated 2 wk after xenotransplantation. The resected specimens of the tumor, 2 wk after xenotransplantation, highly expressed FasL but not programmed death ligand-1 (PD-L1) by immunohistochemical staining. FasL highly expressed cancer cells xenotransplanted 2 wk ago were resistant to TCRαβ-CD8 γδT cells injection. These results suggested that apoptosis of Fas-positive TCRαβ-CD8 γδT cells may be induced by a Fas-mediated signal after interacting with FasL-positive cancer cells.

Citing Articles

Advancements in γδT cell engineering: paving the way for enhanced cancer immunotherapy.

Yuan M, Wang W, Hawes I, Han J, Yao Z, Bertaina A Front Immunol. 2024; 15:1360237.

PMID: 38576617 PMC: 10991697. DOI: 10.3389/fimmu.2024.1360237.

Single-cell sequencing on CD8 TILs revealed the nature of exhausted T cells recognizing neoantigen and cancer/testis antigen in non-small cell lung cancer.

Komuro H, Shinohara S, Fukushima Y, Demachi-Okamura A, Muraoka D, Masago K J Immunother Cancer. 2023; 11(8).

PMID: 37544663 PMC: 10407349. DOI: 10.1136/jitc-2023-007180.

Re-generation of cytotoxic γδT cells with distinctive signatures from human γδT-derived iPSCs.

Murai N, Koyanagi-Aoi M, Terashi H, Aoi T Stem Cell Reports. 2023; 18(4):853-868.

PMID: 36963392 PMC: 10147660. DOI: 10.1016/j.stemcr.2023.02.010.

Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities.

Chen L, Chen F, Niu H, Li J, Pu Y, Yang C Front Immunol. 2022; 13:871661.

PMID: 35911706 PMC: 9334018. DOI: 10.3389/fimmu.2022.871661.

Relationship between Kita-Kyushu Lung Cancer antigen-1 expression and prognosis of cases with lung squamous cell carcinoma.

Ichiki Y, Fukuyama T, Ohmiya H, Ueno M, Yanagi S, Kanasaki Y Transl Cancer Res. 2022; 10(12):5212-5221.

PMID: 35116371 PMC: 8798488. DOI: 10.21037/tcr-21-1581.

References

Szymczak A, Workman C, Wang Y, Vignali K, Dilioglou S, Vanin E . Correction of multi-gene deficiency in vivo using a single 'self-cleaving' 2A peptide-based retroviral vector. Nat Biotechnol. 2004; 22(5):589-94. DOI: 10.1038/nbt957. View

Didkowska J, Wojciechowska U, Manczuk M, Lobaszewski J . Lung cancer epidemiology: contemporary and future challenges worldwide. Ann Transl Med. 2016; 4(8):150. PMC: 4860480. DOI: 10.21037/atm.2016.03.11. View

Hirata H, Takahashi A, Kobayashi S, Yonehara S, Sawai H, Okazaki T . Caspases are activated in a branched protease cascade and control distinct downstream processes in Fas-induced apoptosis. J Exp Med. 1998; 187(4):587-600. PMC: 2212161. DOI: 10.1084/jem.187.4.587. View

Motz G, Santoro S, Wang L, Garrabrant T, Lastra R, Hagemann I . Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014; 20(6):607-15. PMC: 4060245. DOI: 10.1038/nm.3541. View

Norell H, Moretta A, Silva-Santos B, Moretta L . At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias. J Leukoc Biol. 2013; 94(6):1123-39. DOI: 10.1189/jlb.0613312. View

Hanagiri T, Shigematsu Y, Kuroda K, Baba T, Shiota H, Ichiki Y . Antitumor activity of human γδ T cells transducted with CD8 and with T-cell receptors of tumor-specific cytotoxic T lymphocytes. Cancer Sci. 2012; 103(8):1414-9. PMC: 7659244. DOI: 10.1111/j.1349-7006.2012.02337.x. View

Ichiki Y, Shigematsu Y, Baba T, Shiota H, Fukuyama T, Nagata Y . Development of adoptive immunotherapy with KK-LC-1-specific TCR-transduced γδT cells against lung cancer cells. Cancer Sci. 2020; 111(11):4021-4030. PMC: 7648040. DOI: 10.1111/cas.14612. View

Hiasa A, Nishikawa H, Hirayama M, Kitano S, Okamoto S, Chono H . Rapid alphabeta TCR-mediated responses in gammadelta T cells transduced with cancer-specific TCR genes. Gene Ther. 2009; 16(5):620-8. DOI: 10.1038/gt.2009.6. View

Hayday A . [gamma][delta] cells: a right time and a right place for a conserved third way of protection. Annu Rev Immunol. 2000; 18:975-1026. DOI: 10.1146/annurev.immunol.18.1.975. View

10.

Arai H, Gordon D, Nabel E, Nabel G . Gene transfer of Fas ligand induces tumor regression in vivo. Proc Natl Acad Sci U S A. 1998; 94(25):13862-7. PMC: 28398. DOI: 10.1073/pnas.94.25.13862. View

11.

Stevanovic S, Pasetto A, Helman S, Gartner J, Prickett T, Howie B . Landscape of immunogenic tumor antigens in successful immunotherapy of virally induced epithelial cancer. Science. 2017; 356(6334):200-205. PMC: 6295311. DOI: 10.1126/science.aak9510. View

12.

Strasser A, Jost P, Nagata S . The many roles of FAS receptor signaling in the immune system. Immunity. 2009; 30(2):180-92. PMC: 2956119. DOI: 10.1016/j.immuni.2009.01.001. View

13.

Suda T, Takahashi T, Golstein P, Nagata S . Molecular cloning and expression of the Fas ligand, a novel member of the tumor necrosis factor family. Cell. 1993; 75(6):1169-78. DOI: 10.1016/0092-8674(93)90326-l. View

14.

Fukuyama T, Hanagiri T, Takenoyama M, Ichiki Y, Mizukami M, So T . Identification of a new cancer/germline gene, KK-LC-1, encoding an antigen recognized by autologous CTL induced on human lung adenocarcinoma. Cancer Res. 2006; 66(9):4922-8. DOI: 10.1158/0008-5472.CAN-05-3840. View

15.

Seino K, Kayagaki N, Okumura K, Yagita H . Antitumor effect of locally produced CD95 ligand. Nat Med. 1997; 3(2):165-70. DOI: 10.1038/nm0297-165. View

16.

Herbst R, Baas P, Kim D, Felip E, Perez-Gracia J, Han J . Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial. Lancet. 2015; 387(10027):1540-1550. DOI: 10.1016/S0140-6736(15)01281-7. View

17.

Robbins P, Morgan R, Feldman S, Yang J, Sherry R, Dudley M . Tumor regression in patients with metastatic synovial cell sarcoma and melanoma using genetically engineered lymphocytes reactive with NY-ESO-1. J Clin Oncol. 2011; 29(7):917-24. PMC: 3068063. DOI: 10.1200/JCO.2010.32.2537. View

18.

Sugaya M, Takenoyama M, Osaki T, Yasuda M, Nagashima A, Sugio K . Establishment of 15 cancer cell lines from patients with lung cancer and the potential tools for immunotherapy. Chest. 2002; 122(1):282-8. DOI: 10.1378/chest.122.1.282. View

19.

Mazar J, Thomas M, Bezrukov L, Chanturia A, Pekkurnaz G, Yin S . Cytotoxicity mediated by the Fas ligand (FasL)-activated apoptotic pathway in stem cells. J Biol Chem. 2009; 284(33):22022-22028. PMC: 2755926. DOI: 10.1074/jbc.M109.032235. View

20.

Reck M, Rodriguez-Abreu D, Robinson A, Hui R, Csoszi T, Fulop A . Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer. N Engl J Med. 2016; 375(19):1823-1833. DOI: 10.1056/NEJMoa1606774. View